Potentially Clinically Important Inaccuracies in Testing for the Lupus Anticoagulant: an Analysis of Results from three Surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation

Summary

The identification of the presence of antiphospholipid in plasma is recognised to be of diagnostic and prognostic importance in subjects with thrombotic disease, recurrent miscarriage or collagen vascular disorders. A number of coagulation assays are currently employed for the detection of lupus anticoagulant (LA), many of which are influenced by reagent dependent and methodological variables.

In the present study lyophilised plasma samples from three subjects with “strong”, “weak” and “absent” LA were tested in 220 centres. The most commonly used tests for LA were Activated Partial Thromboplastin Time (APTT), Dilute Russell Viper Venom Time (DRVVT) and Kaolin Clotting Time (KCT). Median DRVVT ratios were 1.75, 1.17 and 1.10 for the three samples. The presence of a strong LA was not detected by 4% of laboratories. The correct diagnosis was made by 94% of users of DRVVT and 85% of users of KCT. A weak LA was not detected by over half of centres. Correction was observed on addition of plasma and also in platelet neutralisation. The correct diagnosis was made by 37% of users of DRVVT and 27% of users of KCT. Lupus Anticoagulant was falsely considered to be present in a Factor IX deficient plasma by approximately one quarter of laboratories. Amongst users of DRVVT and KCT absence of LA in this sample was correctly reported by 73% and 69% of centres respectively.

The accuracy of testing for LA in the present study is suboptimal and this is likely to have important clinical consequences. There is clearly a need for greater conformity in the selection and performance of LA tests to facilitate accurate diagnosis of this important group of disorders.

• References

• 1 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta2 glycoprotein (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4122
• 2 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1557
• 3 Machin SJ, Giddings J, Greaves M, Hutton RA, Mackie IJ, Malia RG, Tabemer DA. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885-889
• 4 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of Activated Protein C and its co-factor Protein S by antiphospholipid antibodies. Brit J Haem 1990; 76: 101-107
• 5 Machin SJ, Giddings J, Greaves M, Hutton RA, Mackie IJ, Malia RG, Taberner DA. Detection of the lupus-like anticoagulant: Current laboratory practice in the United Kingdom. J Clin Pathol 1990; 43: 73-85
• 6 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997
• 7 Roussi J, Roisin JP, Goguel A. Lupus anticoagulants. First French Interlaboratory Etalonorme Survey. Am J Clin Pathol 1996; 105: 788-893
• 8 Galli M, Finazzi G, Bevers EM. Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and beta2 glycoprotein 1-dependent antiphospholipid antibodies. Blood 1995; 86: 617-723
• 9 Martin BA, Branch DW, Rodgers GM. Sensitivity of the activated partial thromboplastin time, the dilute Russell’s viper venom time, and the kaolin clotting time for the detection of the lupus anticoagulant: a direct comparison using plasma dilutions. Blood Coag Fibrinolysis 1996; 7: 31-38
• 10 Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost 1995; 74: 1597-1603
• 11 Haemostasis Committee of the “Societe Francaise De Biologie Clinique”. Laboratory heterogeneity of the lupus anticoagulant: a multicentre study using differing clotting assays on a panel of 78 samples Thromb Res 1992; 66: 349-364
• 12 Kelsey PR, Stevenson KJ, Poller L. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time: The central role of phosphatidyl serine. Thromb Haemost 1984; 52: 172-185
• 13 Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Brit J Haematol 1994; 87: 94-99
• 14 Forastiero RR, Cerrato GS, Carreras LO. Evaluation of the recently described tests for detection of the lupus anticoagulant. Thromb Haemost 1994; 72: 728-833
• 15 Sletnes KE, Graven K, Wisloff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Res 1992; 66: 43-53
• 16 Kaczor DA, Bickford NN, Triplett DA. Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing. Am J Clin Pathol 1991; 95: 408-411
• 17 Clyne LP, Yen Y, Kriz NS, Breitenstein MG. The lupus anticoagulant: high incidence of negative mixing studies in a human immunodeficiency viruspositive population. Arch Pathol Lab Med 1993; 117: 595-601
• 18 Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-931